Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

ADX-324-302

17 evidence topics · 4 sources

Objective
Location and study date
UK research ethics committee opinion
Study design
Registry design details
FieldReported value
Allocation“Non-Randomized”
Interventional model“Parallel Assignment”
Masking“Double”
Eligibility criteria
Treatment
Registry interventions
InterventionReported description
ADX-324 Dose Level 1“siRNA duplex oligonucleotide”
ADX-324 Dose Level 2“siRNA duplex oligonucleotide”
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No results are available. The extension began in April 2026 and has an estimated primary completion date of June 2030. Allocation is non-randomized and every participant receives onvuzosiran, so the extension has no concurrent control group for safety or attack-rate comparisons. The core-study assignment remains masked through alternating onvuzosiran and placebo injections in the every-6-months group; the extension itself is not blinded to active treatment. Enrollment is limited to participants who completed STOP-HAE, and participants with a negative reaction to study drug in STOP-HAE are excluded, so the extension population may under-represent participants who did not tolerate or did not continue onvuzosiran. The primary endpoint is the incidence and severity of treatment-emergent adverse events through Month 36, and the monthly attack rate is a secondary endpoint. Planned enrollment is approximately 90 participants, which limits the detection of uncommon adverse events. No statistical analysis plan or analysis population definitions have been published.